Vir Biotechnology Reports Positive Results in Clinical Trials for Hepatitis Delta Treatment
Vir Biotechnology announced that its experimental combination treatment for chronic hepatitis delta met its primary phase 3 trial goal and showed sustained suppression in phase 2.
FTMQ Business, written by our newsroom0 views

Vir Biotechnology announced on Sunday that its experimental combination treatment for chronic hepatitis delta met its primary goal in a phase 3 clinical trial. Seeking Alpha Markets and Seeking Alpha both reported that separate phase 2 results showed sustained suppression of the virus in patients who stopped treatment. [1][4]
Mugglehead Investment Magazine reported that Vir Biotechnology met the phase 3 hepatitis delta endpoint with a 44 percent response rate. Quantisnow also reported that the primary endpoint was met in the pivotal phase 3 trial. Additionally, GuruFocus reported promising phase 2 trial results for chronic hepatitis delta. [3][5][6]
Vir Biotechnology was founded in 2016 and focuses on engineering antibodies to treat viral infections and related conditions. The company maintains a development pipeline targeting chronic hepatitis delta virus and collaborates with partners such as Alnylam Pharmaceuticals, Brii Biosciences Limited, GlaxoSmithKline Biologicals, and the Gates Foundation. [8]
In short
- Vir Biotechnology announced that its experimental combination treatment for chronic hepatitis delta met its primary endpoint in a phase 3 clinical trial.
- Mugglehead Investment Magazine reported a 44 percent response rate in the phase 3 trial.
- Phase 2 clinical trial results showed sustained viral suppression in patients who stopped treatment.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Vir Biotechnology reports positive hepatitis results, early signs of possible cureSeeking Alpha Markets, 9d ago (the report this story comes from)
- [2]Vir Biotechnology, Inc. (VIR) Stock Price, News, Quote & HistoryYahoo! Finance Canada, 9d ago
- [3]Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3...Quantisnow, 9d ago
- [4]Vir Biotechnology reports positive hepatitis results, early signs of possible cure (VIR:NASDAQ)Seeking Alpha, 9d ago
- [5]Vir Biotechnology meets Phase 3 hepatitis delta endpoint with 44% responseMugglehead Investment Magazine, 9d ago
- [6]Vir Biotechnology (VIR) Reports Promising Phase 2 Results for ChGuruFocus, 9d ago
Background
- [7]List of S&P 600 companies on Wikipedia
- [8]Vir Biotechnology on Grokipedia
Our newsroom writes these reports with the help of software, from the 8 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Business
Earlier reports of ours on the same people and subjects.
- Anthropic updates usage policy to ban cruel treatment of Claude AICorporate & Earnings, 40d ago
More in Stocks & Bonds
- Norwegian energy company Equinor suffers cyberattack on IT systems5h ago
- Nvidia Beats Earnings Expectations as Former Chief Seeks Return5h ago
- Paul Tudor Jones investment firm buys Iridium stake and alters ETF portfolio1d ago
- Australian Financial Review launches three new equity indices to tackle concentration2d ago
- Wall Street finishes mixed as leadership uncertainty at Nvidia weighs on tech stocks2d ago
- Oil prices steady as Middle East shipping risks offset supply surplus2d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.